Katherine M. Moxley
Expertise in
14
conditions

Dr. Katherine M. Moxley

Obstetrics and Gynecology
12697 E 51st St, 
Tulsa, OK 
Accepting New Patients
Expertise in
14
conditions
12697 E 51st St, 
Tulsa, OK 

Overview

Katherine M. Moxley, MD, MS, is a board-certified, independent obstetrician and gynecologist (OB-GYN) and gynecologic oncologist at Ascension St. John in Tulsa, Oklahoma. She listens to understand you and your preferences as a woman. Then Dr. Moxley works with you to deliver compassionate, personalized prenatal care throughout pregnancy, labor, and delivery.

Dr. Moxley is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Gastrostomy.

Dr. Moxley is board certified in The American Board Of Obstetrics And Gynecology - Gynecologic Oncology and The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. She is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 15 clinical trials. Dr. Moxley is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in OK

Board Certifications

The American Board Of Obstetrics And Gynecology - Gynecologic Oncology
The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology

Fellowships

University of Oklahoma School of Medicine

Hospital Affiliations

Ascension St. John Medical Center
Hillcrest Medical Center
Ascension St John Medical Center
Saint Francis Hospital South, LLC
Oklahoma State University Medical Center
Saint Francis Hospital, Inc

Languages Spoken

English
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
CommunityCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Priority Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Oklahoma Cancer Specialist and Research Institute
12697 E 51st St, Tulsa, OK 74146

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Radiation, Drug
Study Drugs: Atezolizumab, Cisplatin
Study Phase: Phase 1
A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer
A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Radiation, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Paclitaxel, Ruxolitinib phosphate
Study Phase: Phase 1/Phase 2
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 9 Less Clinical Trials

44 Total Publications

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
Journal: Gynecologic oncology
Published: July 11, 2025
Similar Doctors
Expertise in
20
conditions
Dr. Michael A. Gold
Obstetrics and Gynecology
Expertise in
20
conditions
Dr. Michael A. Gold
Obstetrics and Gynecology
Referral may be required

Oklahoma Cancer Specialist And Research Institute

12697 E 51st St, 
Tulsa, OK 
 (0.1 miles away)
918-505-3200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael A. Gold, MD, is a board-certified, independent gynecologic oncologist at Ascension St. John in Tulsa, Oklahoma. Dr. Gold diagnoses and treats women's reproductive cancer affecting the cervix, uterus and ovaries and vulva. Dr. Gold is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Lymphadenectomy, and Bladder Reconstruction. Dr. Gold is board certified in The American Board Of Obstetrics And Gynecology - Gynecologic Oncology and The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. Dr. Gold is currently accepting new patients.

Expertise in
15
conditions
Dr. Eric D. Thomas
Obstetrics and Gynecology
Expertise in
15
conditions
Dr. Eric D. Thomas
Obstetrics and Gynecology
Referral may be required

Oklahoma Cancer Specialist And Research Institute

12697 E 51st St, 
Tulsa, OK 
 (0.1 miles away)
918-505-3200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eric D. Thomas, MD, is a board-certified, independent obstetrician and gynecologist (OB-GYN) and gynecologic oncologist at Ascension St. John in Tulsa, Oklahoma. He listens to understand you and your preferences as a woman. Then Dr. Thomas works with you to deliver compassionate, personalized prenatal care throughout pregnancy, labor, and delivery. Dr. Thomas also specializes in female reproductive health conditions, menopause care, emotional health, breast health and more. Dr. Thomas is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Oophorectomy, and Bladder Reconstruction. Dr. Thomas is board certified in The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. Dr. Thomas is currently accepting new patients.

Expertise in
14
conditions
Dr. Rachel L. Gibbs
Obstetrics and Gynecology
Expertise in
14
conditions
Dr. Rachel L. Gibbs
Obstetrics and Gynecology
Referral may be required

Warren Clinic Gynecology

6465 South Yale Avenue, Suite 605, 
Tulsa, OK 
 (4.9 miles away)
918-502-4040
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Dr. Gibbs is a board certified gynecologist who specializes in minimally invasive gynecologic surgery. Dr. Gibbs is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Uterine Prolapse, Female Genital Sores, Rectocele, Vitiligo, and Hysterectomy. Dr. Gibbs is currently accepting new patients.

Frequently Asked Questions about Dr. Katherine M. Moxley

How do I make an appointment with Dr. Katherine M. Moxley?

You can book an appointment with Dr. Katherine M. Moxley by calling their office at 918-505-3200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Katherine M. Moxley a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Katherine M. Moxley is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Katherine M. Moxley specialize in?

While Dr. Katherine M. Moxley is a Obstetrics and Gynecology, they have specific expertise in Endometrial Cancer, Ovarian Cancer, and Vulvar Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Katherine M. Moxley participate in research or clinical trials?

Yes. Dr. Katherine M. Moxley has published 44 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Katherine M. Moxley's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Katherine M. Moxley accept my insurance?

Dr. Katherine M. Moxley accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 918-505-3200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moxley's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile